FDA Letter API

Performance Nutrition Formulators LLC dba VMI Sports

Letter data

Company
Performance Nutrition Formulators LLC dba VMI Sports
Recipient
Mr. Thomas M. Reilly, Mr. Frank Fenimore Jr. | President/Partner, CEO/ Partner | Performance Nutrition Formulators LLC dba VMI Sports | 100 Tec Street Unit B | Hicksville | , | NY | 11801 | United States
Issue date
2023-02-09
Posted date
Not available
FDA office
Center for Food Safety and Applied Nutrition (CFSAN)
Subject
Not available
Product
Dietary Supplements
CMS ID
543959
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Performance Nutrition Formulators LLC dba VMI Sports MARCS-CMS 543959 — February 09, 2023 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED Product: Dietary Supplements Recipient: Recipient Name Mr. Thomas M. Reilly, Mr. Frank Fenimore Jr. Recipient Title President/Partner, CEO/ Partner Performance Nutrition Formulators LLC dba VMI Sports 100 Tec Street Unit B Hicksville , NY 11801 United States Issuing Office: Center for Food Safety and Applied Nutrition (CFSAN) United States Dear Mr. Reilly and Mr. Fenimore Jr.: The Food and Drug Administration has completed evaluation of your firm's corrective actions in response to our Warning Letter CMS# 543959, issued on May 18, 2018. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Lillian Aveta Acting Director, Compliance Branch Office of Human and Animal Food Operations East Division 1 Content current as of: 02/09/2023 Regulated Product(s) Dietary Supplements